2 weeks ago
Aurobindo's Eugia Pharma Telangana Unit Gets USFDA Warning Letter
A big medicine company called Aurobindo Pharma has a factory in Telangana, India, where it makes medicines.
Scientists from the United States government, called the FDA, visited the factory to check that everything is safe.
They looked around the factory for almost two weeks.
After the visit, they found four problems that need to be fixed.
Because of these problems, the FDA sent the company a serious letter called a warning letter.
This letter says the factory must fix the problems.
Aurobindo says the letter will not affect the medicines that people get in America.
The factory will keep sending medicines to the US as before.
The company will now work on making the FDA happy again.
Aurobindo Pharma said the USFDA has issued a warning letter to a formulation facility of its arm Eugia Pharma Specialities Ltd in Telangana.
The USFDA inspected Unit-I, the formulation manufacturing facility, from February 16 to February 27, 2026.
The inspection concluded with four observations and the facility was classified as 'official action indicated' (OAI).
Following the OAI determination, the unit received a warning letter from the US health regulator.
The company said there is no impact on existing supplies to the US markets.
- Who
- Aurobindo Pharma, its subsidiary Eugia Pharma Specialities Ltd, and the USFDA
- What
- The USFDA issued a warning letter to Eugia Pharma's Unit-I formulation manufacturing facility.
- Where
- Unit-I formulation facility of Eugia Pharma Specialities Ltd in Telangana, India.
- When
- Announced on a Friday; the USFDA inspected the facility from February 16 to February 27, 2026.
- Why
- The inspection concluded with four observations and the facility was classified as 'official action indicated' (OAI), prompting the warning letter.
Key facts
- Company
- Aurobindo Pharma
- Affected subsidiary
- Eugia Pharma Specialities Ltd
- Facility
- Unit-I formulation manufacturing facility
- Location
- Telangana, India
- Inspection period
- February 16-27, 2026
- Inspection observations
- 4
- Regulator designation
- Official Action Indicated (OAI)
- Impact on US supplies
- No impact, according to the company










